CliffBio
biologic

Tecentriq

atezolizumab

Loss of exclusivityMay 2028projected — 12-year biologic exclusivity estimate
CompanyGenentech →See this company's full patent-cliff portfolio

Drug detail

Brand nameTecentriq
Active ingredientatezolizumab
Strength1,200MG/20ML (60MG/ML)
Dosage formInjection
RouteIntravenous
ModalityBiologic
FDA approvalMay 2016
Marketing statusRx

More from Genentech

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.